Validity of an inertial measurement unit to assess pelvic orientation angles during gait, sit-stand transfers and step-up transfers: Comparison with an optoelectronic motion capture system.

An inertial measurement unit (IMU) allows kinematic evaluation of human motion with fewer operational constraints than a gold standard optoelectronic motion capture (MOCAP) system. The study's aim was to compare IMU and MOCAP measurements of dynamic pelvic orientation angles during different activities of daily life (ADL): gait, sit-to-stand (STS) transfers and block step-up (BS) transfers. A single IMU was attached onto the lower back in seventeen healthy participants (8F/9 M, age 19-31 years; BMI < 25) and optical skin markers were attached onto anatomical pelvic landmarks for MOCAP measurements. Comparisons between IMU and MOCAP by Bland-Altman plots demonstrated that measurements were between 2SD of the absolute difference and Pearson's correlation coefficients were between 0.85 and 0.94. Frontal plane pelvic angle estimations achieved a RMSE in the range of [2.7°-4.5°] and sagittal plane measurements achieved a RMSE in the range of [2.7°-8.9°] which were both lowest in gait. Waveform peak detection times demonstrated ICCs between 0.96 and 1.00. These results are in accordance to other studies comparing IMU and MOCAP measurements with different applications and suggest that an IMU is a valid tool to measure dynamic pelvic angles during various activities of daily life which could be applied to monitor rehabilitation in a wide variety of musculoskeletal disorders.

Review of fluvoxamine safety database.

A review of the safety and tolerability of fluvoxamine in worldwide marketing studies involving 24,624 patients, predominantly receiving fluvoxamine treatment in uncontrolled studies in depression, has been conducted. There was a marked preponderance of female patients and patients aged between 30 and 50 years. The majority of patients were treated for 6 weeks, with the most frequent modal total daily dose being 100mg. The greatest proportion of adverse experiences occurring, by COSTART body system, affected the digestive system (24.1%), the nervous system (23.7%), and the body as a whole (15.3%). The only adverse experience with an incidence greater than 10% was nausea (15.7%), with somnolence (6.9%) and asthenia (6.2%) as the next most frequent experiences. Notably, the rates of agitation and anxiety were only 1.4 and 1.3%, respectively. The incidences of adverse experiences increased with age, and were slightly higher in females than males. 15.1% of patients discontinued treatment prematurely as a result of adverse experiences, principally nausea, dizziness, vomiting, somnolence, abdominal pain, and headache. The overall incidence of serious adverse events associated with fluvoxamine treatment was 2.5%, and the incidence of overall suicidality, including suicidal ideation, overdose, and intentional overdose as well as attempted and completed acts of suicide, was remarkably low at 0.8%.

Safety database on fluvoxamine: analysis and report.

A review was conducted of the safety and tolerability of fluvoxamine in 54 worldwide marketing studies that enrolled 24,624 patients, the majority of whom were treated with fluvoxamine in uncontrolled studies in depression. In accordance with the general epidemiologic distribution of depressive disorder, female patients and patients aged between 30 and 50 years predominated. The majority of patients were treated for 6 weeks, the most frequent, or modal, total daily dose being 100 mg. Overall, 57.4% of the patients exposed to fluvoxamine did not have any adverse experiences. The greatest proportion of adverse experiences, as defined using COSTART body systems, affected the digestive system (24.1%), the nervous system (23.7%), and the body as a whole (15.3%). The only adverse experience with an incidence greater than 10% was nausea (15.7%); somnolence (6.9%) and asthenia (6.2%) were the next most frequent adverse experiences. Notably, the rates of agitation and anxiety were only 1.4% and 1.3%, respectively. The incidences of adverse experiences generally increased with age and were slightly higher in females than in males. In total, 15.1% of patients discontinued treatment prematurely as a result of adverse experiences, principally nausea, dizziness, vomiting, somnolence, abdominal pain, and headache. The overall incidence of serious adverse events in association with fluvoxamine treatment was 2.5% when U.S. Food and Drug Administration criteria and the most conservative approach, without causality judgments, were used.(ABSTRACT TRUNCATED AT 250 WORDS)